Hutchmed China Ltd., supported by Li Ka-shing, is selling a 45% stake in its health unit for $608 million to focus on core operations. The deal with Chinese companies will generate capital for the development of cancer and immunological treatments.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing